Healthcare Equipment and Supplies
Company Overview of Capnia, Inc.
Capnia, Inc. develops diagnostics and therapeutics based on its proprietary technology for precision metering of gas flow primarily in the United States. The company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to the degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has completed phase II clinical trials for the treatment of symptoms related to allergic rhinitis. The company was founded in 1999 and is headquartered in Redwood City, California.
3 Twin Dolphin Drive
Redwood City, CA 94065
Founded in 1999
Key Executives for Capnia, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $433.1K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $121.2K
Vice President of Research and Development
Total Annual Compensation: $246.8K
Compensation as of Fiscal Year 2014.
Capnia, Inc. Key Developments
Capnia, Inc. Appoints Edward Ebbers as Chief Commercial Officer
Apr 13 15
Capnia, Inc. announced the appointment of Edward Ebbers as Chief Commercial Officer, effective April 13, 2015. Mr. Ebbers will be responsible for Capnia's commercial organization, including managing the ongoing commercial rollout of the company's product, CoSense®. Prior to joining Capnia, Mr. Ebbers served as Vice President, Worldwide Marketing, Ophthalmology Products at Clarity Medical Systems.
Capnia, Inc. Announces Earnings Results for the Fourth Quarter and Year Ended December 30, 2014
Mar 10 15
Capnia, Inc. announced earnings results for the fourth quarter and year ended December 30, 2014. For the quarter, the company reported operating loss of $1,845,000 compared to $559,000 a year ago. Net loss and comprehensive loss was $7,854,000 compared to $974,000 a year ago. Basic and diluted net loss per common share was $2.23 compared to $1.82 a year ago.
For the year, the company reported operating loss of $5,160,000 compared to $847,000 a year ago. Net loss and comprehensive loss was $13,875,000 compared to $3,707,000 a year ago. Basic and diluted net loss per common share was $10.92 compared to $5.10 a year ago.
Capnia, Inc. Applies Application to the U.S. Food and Drug Administration for its Nasal, Non-Inhaled Carbon Dioxide Technology for the Treatment of Trigeminal Neuralgia
Jan 8 15
Capnia, Inc. announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Orphan Drug Designation for its nasal, non-inhaled carbon dioxide (nasal CO2) technology for the treatment of trigeminal neuralgia (TN). TN is a clinical condition characterized by debilitating pain in regions of the face innervated by one or more divisions of the trigeminal nerve. The pain is typically described as intense, sharp and stabbing, and is often described as one of the most painful conditions known to humans. It may develop without apparent cause or be a result of another diagnosed disorder, including multiple sclerosis and herpes zoster. The company’s therapeutic technology uses nasal, non-inhaled CO2, delivered at a low-flow rate into the nasal cavity to alleviate symptoms of allergies as well as pain disorders related to the trigeminal nerve. The company developed Serenz for the treatment of allergy symptoms, and has completed multiple clinical trials for the treatment of pain (such as migraine) using this technology. The use of company’s nasal CO2 product for the treatment of TN is supported by preclinical and clinical data demonstrating that CO2 may inhibit sensory nerve activation, subsequent release of neuropeptides and alleviate trigeminally mediated pain. Collectively, these data suggest that nasal CO2 may provide relief of symptoms associated with TN. In the U.S., under the Orphan Drug Act, the FDA's Office of Orphan Products Development grants orphan drug status to a drug intended to treat a rare disease or condition, which is generally a disease that affects fewer than 200,000 individuals in the country. Upon approval, the designation would provide the company’s nasal CO2 therapeutic with certain benefits, including seven years of U.S. market exclusivity in the specified indication if the company complies with certain FDA requirements. Additional incentives for the company would include tax credits related to qualified clinical trial expenses and a possible exemption from FDA application fees.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|